Presbia PLC is a development-stage ophthalmic medical device company focused on designing and commercializing minimally invasive solutions for presbyopia, the age-related loss of near vision. The company’s principal product, the Presbia Flexivue Microlens, is a bio-flexible hydrogel implant positioned within the corneal stroma to restore near vision while preserving distance sight. This proprietary inlay is engineered to adjust focal power through natural accommodation, offering a reversible alternative to permanent surgical procedures such as multifocal laser ablations or lens replacements.
Founded in 2006 and headquartered in Dublin, Ireland, Presbia has conducted multiple clinical trials across Europe and Australia to establish the safety and efficacy of the Flexivue Microlens. The device earned CE Mark approval in 2015, enabling commercial distribution throughout the European Economic Area. Post-approval studies and physician training programs have expanded the technology’s reach into select markets in the Middle East and Latin America, with additional strategic agreements targeting distributors in Asia Pacific regions.
Presbia’s research and development efforts are overseen by a multidisciplinary team of engineers, ophthalmologists, and vision science experts. The company maintains a robust pipeline of next-generation polymer materials and inlay designs aimed at enhancing biocompatibility and visual performance. Ongoing interaction with key opinion leaders in refractive surgery ensures that product enhancements are informed by real-world surgical feedback and patient outcomes.
Governance at Presbia combines medical expertise with commercial acumen. The executive leadership includes the company’s founder and CEO, who brings over two decades of experience in biomedical research, alongside a board of directors comprised of seasoned medical-device entrepreneurs, clinical advisors, and finance professionals. Presbia continues to pursue regulatory clearances, partnerships, and licensing agreements to broaden global access to its presbyopia solutions.
AI Generated. May Contain Errors.
